Established doxorubicin cardiomyopathy is a lethal disease. When congestive heart failure
develops, mortality is approximately 50%. Extensive research has been done to understand …

Significance: Fatigue is one of the most common symptoms of cancer and its treatment,
manifested in the clinic through weakness and exercise intolerance. These side effects not …

Doxorubicin is a highly effective, first line chemotherapeutic agent used in the management
of hematological and solid tumors. The effective use of doxorubicin in cancer therapy has …

Adriamycin is a potent and broad-spectrum antineoplastic agent that plays a major role in
cancer chemotherapy. Unfortunately, its use has been hampered by conventional toxicities …

Anthracyclines play a major role in the treatment of solid malignancies, but their clinical use
is limited by acute or chronic cardiac toxicity. This is not due to the same molecular action …

Use of the chemotherapeutic agent doxorubicin (Dox) is limited by dose-dependent
cardiotoxic effects. The molecular mechanism underlying these toxicities are incompletely …

Sorafenib, a multi‐kinase inhibitor, is recommended as a new standard therapy for
advanced hepatocellular carcinoma (HCC); however, it also exhibits severe cardiotoxicity …

The clinical use of doxorubicin (Dxr) is limited by its cardiotoxic effects which are mediated
by oxygen radicals. The purpose of this study was to investigate in vivo protective effects of …

This study was designed to investigate the possible mechanisms whereby Curcuma longa
could protect against cardiotoxicity induced by doxorubicin. Administration of doxorubicin …

Background: Ischemia-reperfusion (I/R) injury of the heart as a consequence of myocardial
infarction or cardiac surgery represents a serious clinical problem. One of the most …